Sarcoidosis‐like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response

Abstract

Abstract Neoadjuvant chemoimmunotherapy has demonstrated improved efficacy and prognosis in stage IIa–IIIb patients with non‐small cell lung cancer (NSCLC). Drug‐induced sarcoidosis‐like reaction (DISR), an autoimmune reaction, has been reported as a type of immune‐related adverse event that may mimic disease progression. Here, we report the case of patient with NSCLC who developed DISR during neoadjuvant chemoimmunotherapy and finally achieved pathological complete response after surgery.

Keywords

• drug‐induced sarcoidosis‐like reaction
• neoadjuvant chemoimmunotherapy
• non‐small cell lung cancer
• pathological complete response